Advertising

TSE:CRH

4.99
0.02 (0.40%) 1d
0
Showing 1 to 15 of 90 entries
WATCH
He does not own this one, despite the earnings metrics looking solid and there is no net debt. They missed on a recent quarterly earning, but not a bid deal. They are trading at 7 times cash flow and 7 times EBITDA. He would like to see the ROE improve a bit. Price momentum has picked up so he will be watching it.
biotechnology / pharmaceutical
WEAK BUY
Perhaps sideways period is ending. Breakout, look for volume to support it. Keep in mind that $5 stocks are not being eaten up by institutional investors. As long as retail likes it, it will go up. Looks OK from his technical perspective.
biotechnology / pharmaceutical
COMMENT
It's trending along now. Not worried about it. It'll be rangebound; it's currently right in the middle of this channel. Breaking below the range would be negative.
biotechnology / pharmaceutical
PARTIAL BUY
A $4 stock that's chugging along. It's got a chance now and has room to move. Hold or buy a new half-position.
biotechnology / pharmaceutical
TOP PICK
This company is involved in colonoscopies and aggregates businesses in that space, mostly in the US. It trades at less than 10 times free cash-flow. He expects growth from organic tail winds in the procedure space. Acquisitions are done within existing cash flow. Yield 0%. (Analysts’ price target is $6.08)
biotechnology / pharmaceutical
BUY

He was long about a year ago. It had a rough ride but he is long again now. The valuation has become compelling. Good balance sheet and debt not a problem.

biotechnology / pharmaceutical
COMMENT

Their business has been cut back, which is why the stock price had dropped. Feels they continue to be in the "rinse and repeat" mode. They make an acquisition, amalgamate it, bring it into their operation, and increase the business through their marketing, and then go and make another acquisition. Management feels there is lots and lots of room for them to continue this way. The stock looks like it has built a bit of a base and is trying to move higher. Suspects the worst of the news is out, and the market will probably continue to warm up to it.

biotechnology / pharmaceutical
COMMENT

Had this in his Growth portfolio, and it just didn’t work out. A situation where a company gets oversold. It will probably have a good January bounce because of all the tax loss selling that has probably occurred over the last couple of weeks or months. He is having a hard time with this. Would like to support it on valuation, but in terms of execution it has issues with payor codes changing, and the revenue growth is largely beyond the company's control. They haven't handled the past year very well. He would put this in the "OK" category, but with 10,000 public companies to choose from, it is well low on his list.

biotechnology / pharmaceutical
WATCH

He was one of the first buyers. He sold half his position when it was disproportionately high and then the rest on the way down. The market has lost confidence in management, who also sold a lot of shares in the $7 range. If it broke through $3.30 on heavy volume he would take a good look but there are better options until then.

biotechnology / pharmaceutical
COMMENT

Has been badly beaten up. In 2014, revenues were about $11 million, and are now looking at about $100 million. BV is around $.85, so it is still trading at around 3X BV. The important thing is that insiders have been selling like crazy. When this happens, that is not a good sign. Not a contrarian stock to his way of thinking.

biotechnology / pharmaceutical
DON'T BUY

Thinks management got caught off guard with the Medicare/Medicaid changes. Listening to the calls, he didn’t have a lot of confidence. Their business model is a bit broken now. With the share price and valuation so low, they are not getting as much bang for their buck now. Heading into the tax loss season, this is probably going to be one of the big targets. He would sit on the sidelines, at least until the new year.

biotechnology / pharmaceutical
COMMENT

They are in the US mainly and partner with anesthesiologists, for gut surgeries. There is a whole system in the US as to who can treat whom and what they will pay. These guys have been hit because of lack of organic growth and the concern is whether the reduced amount the Medicaid is willing to pay will impact margins going forward. He thinks it is overdone.

biotechnology / pharmaceutical
PAST TOP PICK

(A Top Pick Nov 16/16. Down 71%.) A few things happened. Have had 2 reimbursement cuts. Hasn’t affecting earnings yet, but it will. It’s been an acquisition story and they’ve been buying anaesthesiology clinics using their stock as currency. That becomes difficult now because of the low stock price.

biotechnology / pharmaceutical
DON'T BUY

It has not done anything at all for him and is on a short leash. It is drifting back now. He would be concerned about tax loss selling soon. There is value there but don’t start a position.

biotechnology / pharmaceutical
TOP PICK

Has been looking at this for over 2 years, and met management repeatedly. Was aware of the Short attack circulating this summer, which had some pretty interesting important points to make. When a share price goes from $12 to around $3, his view is that it was fully priced in and there was a big overreaction by the street. They are exclusively based in the US, and have a medical product that is used by gastroenterologists in the clinics, kind of a Trojan horse for them because they have the clinics that are using the medical product, so have a relationship with them. With a number of the clinics, they have effectively bought 50% of the clinic, which allows them to provide the anaesthesia services on behalf of the doctors who work there. A pristine balance sheet. (Analysts’ price target is $5.)

biotechnology / pharmaceutical
Showing 1 to 15 of 90 entries

CRH Medical Corp.(CRH-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for CRH Medical Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

CRH Medical Corp.(CRH-T) Frequently Asked Questions

What is CRH Medical Corp. stock symbol?

CRH Medical Corp. is a Canadian stock, trading under the symbol CRH-T on the Toronto Stock Exchange (CRH-CT). It is usually referred to as TSX:CRH or CRH-T

Is CRH Medical Corp. a buy or a sell?

In the last year, there was no coverage of CRH Medical Corp. published on Stockchase.

Is CRH Medical Corp. a good investment or a top pick?

CRH Medical Corp. was recommended as a Top Pick by on . Read the latest stock experts ratings for CRH Medical Corp..

Why is CRH Medical Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is CRH Medical Corp. worth watching?

0 stock analysts on Stockchase covered CRH Medical Corp. In the last year. It is a trending stock that is worth watching.

What is CRH Medical Corp. stock price?

On 2021-04-22, CRH Medical Corp. (CRH-T) stock closed at a price of $4.99.